Intratympanic Dexamethasone
Treatment for Meniere's Disease
Typical Dosage: 10-24 mg/mL, 0.3-0.5 mL per injection
Effectiveness
78%
Safety Score
70%
Clinical Trials
8
Participants
3.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
10-24 mg/mL, 0.3-0.5 mL per injection
Time to Effect
Days to 2 weeks
Treatment Duration
As needed, usually 1-3 injections per flare-up or series
Evidence Quality
MODERATENumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$450
Side Effect Mgmt:$50
Total Annual:$2,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.45
Outcome-Based Costs
Cost per Responder
$2,667
Cost per Remission
$4,000
Intratympanic Dexamethasone Outcomes
for Meniere's Disease
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+75%
Remission Rate
+50%
Common Side Effects
Ear discomfort/pain
+15%
Transient vertigo
+7%
Ear infection
+3%
Tympanic membrane perforation
+1%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
3 completed trials for Intratympanic Dexamethasone in Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
NCT02612337COMPLETEDPHASE3
166 participants
INTERVENTIONAL
San Diego, United States
Started: Oct 27, 2015
A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom
NCT02265393COMPLETEDPHASE2
128 participants
INTERVENTIONAL
Berkshire, United Kingdom +14 more
Started: Oct 1, 2014
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
NCT03664674COMPLETEDPHASE3
148 participants
INTERVENTIONAL
Fresno, United States +64 more
Started: Aug 27, 2018